Structure Therapeutics' lead product candidate is GSBR-1290, a highly selective oral GLP-1 receptor agonist, which is being evaluated in multiple mid-stage studies for treating healthy overweight or obese individuals. The Zacks Consensus Estimate is currently pegged at a loss of 23 cents per share. Let's see how things might have shaped up for the upcoming quarterly release. The company plans to file an investigational new drug application to the FDA in the third quarter of 2024 to begin the phase IIb obesi ...

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. In fact, according to Grand View Research, biotech could be worth about $3.88 trillion by 2030. After all, there's always going to be a need for biotech. Fueling even more upside is artificial intelligence, which may be able to create new drugs that can treat untreatable issues. There's even newer innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, gene editing ...

Core Insights - Structure Therapeutics and Novo Nordisk are both targeting the obesity therapy market, with Structure being a pre-revenue biotech and Novo Nordisk having significant revenue and market presence [1][2]. Market Dynamics - The obesity therapy market is not a winner-take-all scenario, allowing for multiple players to coexist. Structure Therapeutics, with no current revenue, has the potential for massive growth by capturing even a small market share [2]. - Novo Nordisk's revenue for the trailing 12 months is $35.5 billion, with the cardiometabolic segment being its fastest-growing area [2]. Product Comparison - Novo Nordisk's Wegovy has shown a weight loss of 12.4% after 68 weeks, while Structure's GS-1290 demonstrated a 6.2% weight loss in just 12 weeks during phase 2a trials. GS-1290 is also a daily tablet, offering a more convenient administration method compared to Wegovy's injection [3][10]. Future Prospects - For Structure Therapeutics to succeed, it must heavily reinvest in R&D after launching GS-1290 to keep pace with Novo Nordisk's advancements [4]. - The company is still in the early stages of development, and while it has potential, the transition from biotech to a major pharmaceutical player is challenging and may take over a decade [5][6]. Competitive Landscape - Structure Therapeutics needs to excel in cardiometabolic medicines, particularly for diabetes and obesity, and must expand its product lineup beyond its current two clinical-stage programs [9]. - There is optimism regarding GS-1290's potential effectiveness compared to Wegovy, which could position Structure favorably in the market if regulatory approvals are obtained [10][11]. Challenges Ahead - Structure has yet to navigate regulatory approvals and establish a proven market competency, and its management has not yet demonstrated the ability to maintain profitability while growing [12].

The capsule-to-tablet PK study was designed to evaluate the tolerability, safety and pharmacokinetics of a new tablet formulation of GSBR-1290 in the given patient population. Data from the capsule-to-tablet PK study showed that treatment with the tablet formulation of GSBR-1290 led to a placebo-adjusted mean weight loss of up to 6.9% at 12 weeks. Image Source: Zacks Investment Research Obesity has become a global health problem as it can cause heart disease, diabetes and stroke, leading to an exponential i ...

Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. Shares of Structure Therapeutics (GPCR -0.30%) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clinical-stage drugmaker developing an orally available therapy, called GSBR-1290. Structure's lead candidate works like semaglutide, the ...

About Structure Therapeutics Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering. Investors: Danielle Keatley Structure Therapeutics Inc. ir@structuretx.com Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on June 5, 2024. Copies of the registration statements can be accessed through the SEC's web ...

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 addition ...

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offer ...

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small mol ...

Qiming has maintained a steady investment pace in 2023 and continued to evaluate and invest in exciting and disruptive areas. Additionally, Qiming strategically participated follow-on investments in high-quality portfolio companies. SHANGHAI, June 4, 2024 /PRNewswire/ -- The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing Partner at Qiming Venture Partners, has become a Forbes Midas Lister for the sixth consecutive ...